Contact
searchSearch
HMP Global
Login

Major Depressive Disorder Topic Center

Study on MDD - stock image
News
Phase II Trial of AL001 for MDD Set to Begin Later this Year
03/24/2025
Jolynn Tumolo
Plans have been announced for a phase II clinical study of investigational lithium therapy AL001 for MDD, focusing on its unique properties and its effect on lithium delivery in the brain compared with marketed lithium salts.
Plans have been announced for a phase II clinical study of investigational lithium therapy AL001 for MDD, focusing on its unique properties and its effect on lithium delivery in the brain compared with marketed lithium salts.
Plans have been announced for a...
03/24/2025
Psych Congress Network
Quiz
Quiz
Cariprazine FDA-Approved Indications
02/21/2025
Meagan Thistle
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as...
02/21/2025
Psych Congress Network
Pill bottle
News
Investigational MDD Drug Shows Favorable Outcome in Interim Analysis
02/18/2025
Jolynn Tumolo
An ongoing phase 2b trial investigating adjunctive ALTO-300 in patients with MDD and inadequate antidepressant response will add 50 participants after results from a planned interim analysis showed favorable findings, Alto Neuroscience...
An ongoing phase 2b trial investigating adjunctive ALTO-300 in patients with MDD and inadequate antidepressant response will add 50 participants after results from a planned interim analysis showed favorable findings, Alto Neuroscience...
An ongoing phase 2b trial...
02/18/2025
Psych Congress Network
The US Food and Drug Administration headquarters sign.
FDA Alerts
FDA Approves Esketamine as Monotherapy for Treatment-Resistant Depression
01/21/2025
Brionna Mendoza
The US Food and Drug Administration (FDA) has approved a supplemental New Drug Application for esketamine CIII nasal spray (marketed as Spravato) as monotherapy for major depressive disorder (MDD) in adults who haven’t responded significantly...
The US Food and Drug Administration (FDA) has approved a supplemental New Drug Application for esketamine CIII nasal spray (marketed as Spravato) as monotherapy for major depressive disorder (MDD) in adults who haven’t responded significantly...
The US Food and Drug...
01/21/2025
Psych Congress Network
Quiz
Quiz
What percentage of people experience hypomanic symptoms during an MDD episode?
01/15/2025
Meagan Thistle
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study...
01/15/2025
Psych Congress Network
Major Depressive Disorder MDD
News
Hypomanic Symptoms in Major Depression Linked With Treatment Resistance
01/03/2025
Jolynn Tumolo
Common in patients with unipolar depression, hypomanic symptoms are associated with both treatment-resistant depression and reduced remission of suicidal thoughts, according to a study in the Journal of Affective Disorders.
Common in patients with unipolar depression, hypomanic symptoms are associated with both treatment-resistant depression and reduced remission of suicidal thoughts, according to a study in the Journal of Affective Disorders.
Common in patients with unipolar...
01/03/2025
Psych Congress Network
DSM-5
Quiz
How does the DSM-5 define 'remission' in MDD?
12/13/2024
Quiz! What is the definition of remission in the context of major depressive disorder (MDD), according to the DSM-5-TR?
Quiz! What is the definition of remission in the context of major depressive disorder (MDD), according to the DSM-5-TR?
Quiz! What is the definition of...
12/13/2024
Psych Congress Network
DSM-5
Quiz
How does the chronicity of depressive symptoms affect MDD treatment and outcomes?
12/11/2024
Meagan Thistle
12/11/2024
Psych Congress Network
depression stock photo
News
Mitophagy-Related Genes in Astrocytes May Serve as MDD Biomarkers
12/05/2024
Jolynn Tumolo
A trio of newly identified mitophagy-related genes in astrocytes are promising biomarkers for diagnosing and treating MDD, according to a study in the Journal of Affective Disorders.
A trio of newly identified mitophagy-related genes in astrocytes are promising biomarkers for diagnosing and treating MDD, according to a study in the Journal of Affective Disorders.
A trio of newly identified...
12/05/2024
Psych Congress Network
quiz
Quiz
What is esketamine indicated to treat?
12/02/2024
Esketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, is indicated in conjunction with an oral antidepressant for the treatment of what? Take the quiz!
Esketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, is indicated in conjunction with an oral antidepressant for the treatment of what? Take the quiz!
Esketamine, a non-competitive...
12/02/2024
Psych Congress Network
Depression
News
Study Reveals Anhedonia Impact on Symptom Severity and Treatment Outcomes in Patients With MDD
11/22/2024
Meagan Thistle
A study presented in a poster at Psych Congress 2024 in Boston, Massachusetts, aimed to understand the characteristics and treatment patterns of patients with MDD who experience prominent anhedonia compared to those who do not or who have low...
A study presented in a poster at Psych Congress 2024 in Boston, Massachusetts, aimed to understand the characteristics and treatment patterns of patients with MDD who experience prominent anhedonia compared to those who do not or who have low...
A study presented in a poster at...
11/22/2024
Psych Congress Network

News

Study on MDD - stock image
News
Phase II Trial of AL001 for MDD Set to Begin Later this Year
03/24/2025
Jolynn Tumolo
Plans have been announced for a phase II clinical study of investigational lithium therapy AL001 for MDD, focusing on its unique properties and its effect on lithium delivery in the brain compared with marketed lithium salts.
Plans have been announced for a phase II clinical study of investigational lithium therapy AL001 for MDD, focusing on its unique properties and its effect on lithium delivery in the brain compared with marketed lithium salts.
Plans have been announced for a...
03/24/2025
Psych Congress Network
Pill bottle
News
Investigational MDD Drug Shows Favorable Outcome in Interim Analysis
02/18/2025
Jolynn Tumolo
An ongoing phase 2b trial investigating adjunctive ALTO-300 in patients with MDD and inadequate antidepressant response will add 50 participants after results from a planned interim analysis showed favorable findings, Alto Neuroscience...
An ongoing phase 2b trial investigating adjunctive ALTO-300 in patients with MDD and inadequate antidepressant response will add 50 participants after results from a planned interim analysis showed favorable findings, Alto Neuroscience...
An ongoing phase 2b trial...
02/18/2025
Psych Congress Network
Major Depressive Disorder MDD
News
Hypomanic Symptoms in Major Depression Linked With Treatment Resistance
01/03/2025
Jolynn Tumolo
Common in patients with unipolar depression, hypomanic symptoms are associated with both treatment-resistant depression and reduced remission of suicidal thoughts, according to a study in the Journal of Affective Disorders.
Common in patients with unipolar depression, hypomanic symptoms are associated with both treatment-resistant depression and reduced remission of suicidal thoughts, according to a study in the Journal of Affective Disorders.
Common in patients with unipolar...
01/03/2025
Psych Congress Network
depression stock photo
News
Mitophagy-Related Genes in Astrocytes May Serve as MDD Biomarkers
12/05/2024
Jolynn Tumolo
A trio of newly identified mitophagy-related genes in astrocytes are promising biomarkers for diagnosing and treating MDD, according to a study in the Journal of Affective Disorders.
A trio of newly identified mitophagy-related genes in astrocytes are promising biomarkers for diagnosing and treating MDD, according to a study in the Journal of Affective Disorders.
A trio of newly identified...
12/05/2024
Psych Congress Network
Depression
News
Study Reveals Anhedonia Impact on Symptom Severity and Treatment Outcomes in Patients With MDD
11/22/2024
Meagan Thistle
A study presented in a poster at Psych Congress 2024 in Boston, Massachusetts, aimed to understand the characteristics and treatment patterns of patients with MDD who experience prominent anhedonia compared to those who do not or who have low...
A study presented in a poster at Psych Congress 2024 in Boston, Massachusetts, aimed to understand the characteristics and treatment patterns of patients with MDD who experience prominent anhedonia compared to those who do not or who have low...
A study presented in a poster at...
11/22/2024
Psych Congress Network
Patient survey
News
Patient Survey Identifies Barriers to TD Treatment
11/06/2024
Jolynn Tumolo
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive...
11/06/2024
Psych Congress Network
depression stock photo
News
Add-on Lumateperone Eases MDD in Patients With Inadequate Antidepressant Response
11/04/2024
Jolynn Tumolo
Adjunctive treatment with the atypical antipsychotic lumateperone improved depressive symptoms and severity more than adjunctive placebo in patients with MDD with inadequate response to previous antidepressant therapy, according to a poster...
Adjunctive treatment with the atypical antipsychotic lumateperone improved depressive symptoms and severity more than adjunctive placebo in patients with MDD with inadequate response to previous antidepressant therapy, according to a poster...
Adjunctive treatment with the...
11/04/2024
Psych Congress Network
Psilocybin
News
Psilocybin May Improve Outcomes More Than Traditional MDD Treatments
10/08/2024
Meagan Thistle
While intensive treatments with psilocybin and the serotonin reuptake inhibitor (SSRI) escitalopram were associated with long-term improvements in major depressive disorder (MDD) symptom severity, recent phase 2 double-blind, randomized,...
While intensive treatments with psilocybin and the serotonin reuptake inhibitor (SSRI) escitalopram were associated with long-term improvements in major depressive disorder (MDD) symptom severity, recent phase 2 double-blind, randomized,...
While intensive treatments with...
10/08/2024
Psych Congress Network
brain netw
News
Patients With Specific Treatment-Resistant Depression Biotype Improve With TMS
09/05/2024
Jolynn Tumolo; Meagan Thistle
Patients with a particular cognitive biotype of treatment-resistant depression are more likely to experience improvement with TMS compared with other patients, study finds.
Patients with a particular cognitive biotype of treatment-resistant depression are more likely to experience improvement with TMS compared with other patients, study finds.
Patients with a particular...
09/05/2024
Psych Congress Network
Doctor and patient
News
Clinician-Level Differences Significantly Affect MDD Prescribing, Outcomes
08/01/2024
Jolynn Tumolo
Antidepressant prescribing patterns and outcomes for patients with MDD vary significantly between prescriber groups, suggest study findings published in JAMA Psychiatry.
Antidepressant prescribing patterns and outcomes for patients with MDD vary significantly between prescriber groups, suggest study findings published in JAMA Psychiatry.
Antidepressant prescribing...
08/01/2024
Psych Congress Network
Study on MDD - stock image
News
Phase II Trial of AL001 for MDD Set to Begin Later this Year
03/24/2025
Jolynn Tumolo
Plans have been announced for a phase II clinical study of investigational lithium therapy AL001 for MDD, focusing on its unique properties and its effect on lithium delivery in the brain compared with marketed lithium salts.
Plans have been announced for a phase II clinical study of investigational lithium therapy AL001 for MDD, focusing on its unique properties and its effect on lithium delivery in the brain compared with marketed lithium salts.
Plans have been announced for a...
03/24/2025
Psych Congress Network
US FDA sign
News
FDA Seeks Clearer Labeling for Transmucosal Buprenorphine Product Dosing
03/24/2025
Jolynn Tumolo
To avoid misperceptions that current labeling for buprenorphine-containing transmucosal products includes a maximum daily dose, the US Food and Drug Administration (FDA) is encouraging the submission of supplemental new drug applications to...
To avoid misperceptions that current labeling for buprenorphine-containing transmucosal products includes a maximum daily dose, the US Food and Drug Administration (FDA) is encouraging the submission of supplemental new drug applications to...
To avoid misperceptions that...
03/24/2025
Psych Congress Network
3 medical professionals stand together talking in the hallway of a medical facility
News
Accelerated Theta-Burst Stimulation Protocol Improves Treatment-Resistant Depression
03/21/2025
Jolynn Tumolo
A novel 78-minute accelerated theta-burst stimulation (aTBS) protocol reduced depression severity in patients with treatment-resistant depression (TRD), according to results from a randomized clinical trial published in JAMA Psychiatry.
A novel 78-minute accelerated theta-burst stimulation (aTBS) protocol reduced depression severity in patients with treatment-resistant depression (TRD), according to results from a randomized clinical trial published in JAMA Psychiatry.
A novel 78-minute accelerated...
03/21/2025
Psych Congress Network
an older man wearing glasses rubs his face in stress tired depression treatment resistant depression
News
Genetic Predispositions to Insomnia, Neuroticism, Linked With Higher Risk for Treatment-Resistant Depression
03/18/2025
Jolynn Tumolo
A genetic predisposition to traits including neuroticism, cognitive function, and sleep patterns were significantly associated with the development of treatment-resistant depression (TRD) in a cohort study published in JAMA Psychiatry.
A genetic predisposition to traits including neuroticism, cognitive function, and sleep patterns were significantly associated with the development of treatment-resistant depression (TRD) in a cohort study published in JAMA Psychiatry.
A genetic predisposition to...
03/18/2025
Psych Congress Network
Woman sitting at bar holding a drink.
News
Semaglutide Reduces Cravings in Adults with Alcohol Use Disorder
03/13/2025
Jolynn Tumolo
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
Nine weeks of low-dose...
03/13/2025
Psych Congress Network
emergency room hospital waiting room reception area
News
Why Aren’t More Emergency Departments Using Medications for OUD Treatment?
03/12/2025
Jolynn Tumolo
Barriers may be hampering the use of medications for opioid use disorder (MOUD) in US emergency departments (EDs), according to results from a systematic review published in the Journal of Substance Use & Addiction Treatment.
Barriers may be hampering the use of medications for opioid use disorder (MOUD) in US emergency departments (EDs), according to results from a systematic review published in the Journal of Substance Use & Addiction Treatment.
Barriers may be hampering the...
03/12/2025
Psych Congress Network
stethoscope with research images in background medical study clinical trial research
News
Machine Learning Predicts Progression to Schizophrenia Within 5 Years
03/12/2025
Jolynn Tumolo
Machine learning models used routine clinical data from electronic health records to predict progression to schizophrenia and bipolar disorder within 5 years for patients with pre-existing mental illness, according to a study published in...
Machine learning models used routine clinical data from electronic health records to predict progression to schizophrenia and bipolar disorder within 5 years for patients with pre-existing mental illness, according to a study published in...
Machine learning models used...
03/12/2025
Psych Congress Network
two researchers look at computer screen in lab medical research
News
Continuous D2 Blockade in First-Episode Schizophrenia Does Not Raise Relapse Risk
03/05/2025
Jolynn Tumolo
More than 5 years of continuous treatment with dopamine D2 receptor-blocking long-acting injectable (LAI) antipsychotics does not appear to increase the risk of breakthrough psychosis in patients with first-episode schizophrenia.
More than 5 years of continuous treatment with dopamine D2 receptor-blocking long-acting injectable (LAI) antipsychotics does not appear to increase the risk of breakthrough psychosis in patients with first-episode schizophrenia.
More than 5 years of continuous...
03/05/2025
Psych Congress Network
A doctor and patient talk
News
Later Life Depressive Symptoms Not Linked With Amyloid Accumulation
03/04/2025
Jolynn Tumolo
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal...
03/04/2025
Psych Congress Network
A woman lies on the couch holding an ice pack to her head
News
Mild TBI Sustained in Traumatic Context Associated With Worse Long-Term Outcomes
03/03/2025
Jolynn Tumolo
Mild traumatic brain injury (mTBI) that occurred in the context of psychological trauma was associated with poorer long-term outcomes, including greater posttraumatic stress disorder (PTSD) severity, postconcussive symptoms, and disability.
Mild traumatic brain injury (mTBI) that occurred in the context of psychological trauma was associated with poorer long-term outcomes, including greater posttraumatic stress disorder (PTSD) severity, postconcussive symptoms, and disability.
Mild traumatic brain injury...
03/03/2025
Neurology

Quizzes

Quiz
Quiz
Cariprazine FDA-Approved Indications
02/21/2025
Meagan Thistle
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as...
02/21/2025
Psych Congress Network
Quiz
Quiz
What percentage of people experience hypomanic symptoms during an MDD episode?
01/15/2025
Meagan Thistle
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study...
01/15/2025
Psych Congress Network
DSM-5
Quiz
How does the DSM-5 define 'remission' in MDD?
12/13/2024
Quiz! What is the definition of remission in the context of major depressive disorder (MDD), according to the DSM-5-TR?
Quiz! What is the definition of remission in the context of major depressive disorder (MDD), according to the DSM-5-TR?
Quiz! What is the definition of...
12/13/2024
Psych Congress Network
DSM-5
Quiz
How does the chronicity of depressive symptoms affect MDD treatment and outcomes?
12/11/2024
Meagan Thistle
12/11/2024
Psych Congress Network
quiz
Quiz
What is esketamine indicated to treat?
12/02/2024
Esketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, is indicated in conjunction with an oral antidepressant for the treatment of what? Take the quiz!
Esketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, is indicated in conjunction with an oral antidepressant for the treatment of what? Take the quiz!
Esketamine, a non-competitive...
12/02/2024
Psych Congress Network
quiz
Quiz
Key Barriers to Tardive Dyskinesia Diagnosis
11/18/2024
The key barriers to a tardive dyskinesia diagnosis DID NOT include which of the following, according to data presented in a poster at Psych Congress 2024? Take the quiz now!
The key barriers to a tardive dyskinesia diagnosis DID NOT include which of the following, according to data presented in a poster at Psych Congress 2024? Take the quiz now!
The key barriers to a tardive...
11/18/2024
Psych Congress Network
pop quiz
Quiz
Esketamine Dosing Schedule for Treatment-Resistant Depression
10/01/2024
During the induction and maintenance phases of esketamine treatment, how frequently should the medication be administered to treat TRD? Take the quiz to test your psychopharmacology knowledge.
During the induction and maintenance phases of esketamine treatment, how frequently should the medication be administered to treat TRD? Take the quiz to test your psychopharmacology knowledge.
During the induction and...
10/01/2024
Psych Congress Network
brain puzzle graphic
Quiz
Treatment Guidelines for Patients With MDD Who Have Not Responded to Current Pharmacotherapy
09/09/2024
Patients with MDD who have undergone an adequate trial of optimized pharmacotherapy but only partial or no response should be reassessed for what? Take the quiz to find out!
Patients with MDD who have undergone an adequate trial of optimized pharmacotherapy but only partial or no response should be reassessed for what? Take the quiz to find out!
Patients with MDD who have...
09/09/2024
Psych Congress Network
quiz
Quiz
Which factor is NOT consideration when choosing an antidepressant medication?
06/28/2024
Which factor is NOT a consideration when choosing an antidepressant medication according to the APA's major depressive disorder practice guidelines? Take the quiz to find out!
Which factor is NOT a consideration when choosing an antidepressant medication according to the APA's major depressive disorder practice guidelines? Take the quiz to find out!
Which factor is NOT a...
06/28/2024
Psych Congress Network
quiz
Quiz
Age-Response Connection in Multilocus Sequential rTMS Therapy for Tinnitus With Comorbid Mental Health Conditions
03/18/2024
According to a recent study, which patient group is more likely to initially show less improvement in tinnitus symptoms when undergoing multilocus sequential rTMS therapy?
According to a recent study, which patient group is more likely to initially show less improvement in tinnitus symptoms when undergoing multilocus sequential rTMS therapy?
According to a recent study,...
03/18/2024
Psych Congress Network
Dr Steven Chan
Expert Insights Quiz
Choosing the Right Digital Therapeutic for MDD Treatment
03/18/2025
Steven Chan, MD, MBA; Meagan Thistle
According to Psych Congress Steering Committee Member Steven Chan, MD, MBA, which of the following are important considerations when selecting and implementing digital therapeutics for the treatment of MDD?
According to Psych Congress Steering Committee Member Steven Chan, MD, MBA, which of the following are important considerations when selecting and implementing digital therapeutics for the treatment of MDD?
According to Psych Congress...
03/18/2025
Psych Congress Network
Did OUD diagnoses increase or decrease in VHA patients?
Quiz
Did OUD diagnoses increase or decrease in VHA patients?
02/25/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
02/25/2025
Psych Congress Network
Charles Raison headshot
Expert Insights Quiz
First-Line Treatment Options for Insomnia
02/21/2025
Charles L. Raison, MD
True or False: According to Psych Congress Steering Committee Member, Charles Raison, MD, the first-line treatment for primary insomnia is medication, including benzodiazepines.
True or False: According to Psych Congress Steering Committee Member, Charles Raison, MD, the first-line treatment for primary insomnia is medication, including benzodiazepines.
True or False: According to...
02/21/2025
Psych Congress Network
Quiz
Quiz
Cariprazine FDA-Approved Indications
02/21/2025
Meagan Thistle
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as...
02/21/2025
Psych Congress Network
How many US Psychiatric Hospitals Provided Medications for OUD?
Quiz
How many US psychiatric hospitals provided medications for OUD?
02/06/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
02/06/2025
Psych Congress Network
Four people ponder with question marks over their heads
Quiz
DSM-5 Quiz: Mood Symptoms in Schizophrenia
02/03/2025
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
02/03/2025
Psych Congress Network
How many people with anxiety disorders receive treatment?
Quiz
How many people with anxiety disorders receive treatment?
01/28/2025
Test your statistical knowledge!
Test your statistical knowledge!
Test your statistical knowledge!
01/28/2025
Psych Congress Network
How can clinicians help patients with ADHD transition from adolescence to adulthood?
Quiz
How can clinicians help patients with ADHD transition from adolescence to adulthood?
01/22/2025
Do you remember this interview with Dr Wilens?
Do you remember this interview with Dr Wilens?
Do you remember this interview...
01/22/2025
Psych Congress Network
Three illustrated faces, one sad, one neutral, one happy, with a human hand picking up the happy face
Quiz
Conditions That Mimic ADHD in Pediatric Patients
01/21/2025
Test your knowledge with this quiz!
Test your knowledge with this quiz!
Test your knowledge with this...
01/21/2025
Psych Congress Network
Quiz
Quiz
What percentage of people experience hypomanic symptoms during an MDD episode?
01/15/2025
Meagan Thistle
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study...
01/15/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use